Reinhard J. Ambros, Ph.D., has served as the global head of the Novartis Venture Fund from 2005-2017 and built one of the largest ~$1bn and most active corporate Biotechnology Venture Funds globally. He led more then 80 new investments and was involved in over 50 exits, IPOs & M&A. As the fund manager he built a team of respected investment managers in Europe and US and established a network with key finance syndicate partners and pharma organizations.
In his former position he was the head of Group Strategic Planning for Novartis AG and led business development and licensing in the cardiovascular and metabolic disease area for Novartis Pharma AG. Earlier in his career he led international project on pharmaceutical product development in various therapeutic areas for Novartis Pharma AG and Hoffmann-La Roche.
Dr. Ambros is the independent lead director of the board of directors of Aileron Therapeutics, he also serves as the chair of the board of directors for Genedata AG (Switzerland) and is a board member of Topadur (Switzerland) and Affluent Medical (France).
He serves as advisor to the German Government’s (BMBF) Go-Bio Fund. Dr. Ambros received a Ph.D. from the University of Regensburg, Germany.